For Healthcare Professionals - United States


Transcatheter Aortic Valve Replacement

  • Confidence Delivered
  • RECAPTURABILITY The new standard in TAVI
  • RECAPTURE Access, Control, Performance
  • CoreValve Evolut R

Latest News


Superior Long-Term Clinical Outcomes

As presented at the ACC 2016 annual meeting, the CoreValve self-expanding, supra-annular valve continues to show a lower rate of stroke or mortality vs surgery, with better hemodynamic performance.

Learn more >


93.3% - Evolut R Survival at 1 Year

Evolut R CE Study 1-year results presented at TCT 2015 demonstrate excellent procedural results with strong safety profile, exceptional outcomes and strong hemodynamic performance.

Learn more >


FDA Approves the CoreValve® Evolut® R System

The Evolut R System is approved for patients with severe aortic stenosis who are at high or extreme risk for surgery and for those with a failed surgical bioprosthesis (TAV in SAV). It is the first and only recapturable and repositionable device available in the U.S., setting a new standard for TAVR.


Driving the Future of TAVR

Now Indicated for Failed Surgical Aortic Bioprosthesis

The CoreValve supra-annular leaflet position—where the frame is least constrained—optimizes blood flow, maximizing the potential effective orifice area (EOA). This is critical due to previous reduction in native EOA from surgical bioprosthesis.

CoreValve Expanded Use Study
Failed Bioprosthetic Surgical Valve (TAV in SAV) >

Latest TAVR Developments

Sign up for periodic updates